Search clinical trials for: XARELTO

Total 252 results

Bayer
Janssen Research & Development, LLC

Completed

A Study Using Electronic Health Information to Learn About Rivaroxaban Compared to Warfarin in Participants With Non-valvular Atrial Fibrillation (NVAF) and Diabetes (RIVA-DM)

Atrial Fibrillation

United States
University of Sao Paulo General Hospital

Completed

Tooth Extraction in Patients With Atrial Fibrillation in Use of New Oral Anticoagulants

Hemorrhage | Atrial Fibrillation | Periodontal Disease

Brazil
Bayer
Janssen, LP

Completed

Study to Gain Insights in Treatment Patterns and Outcomes in Patients With Atherosclerosis Prescribed to Xarelto in Combination With Acetylsalicylic Acid (XATOA)

Atherosclerosis

Germany, Argentina, Brazil, Canada, Denmark, Israel, Korea, Republic of, Lebanon, Luxembourg, Mexico, Norway, Russian Federation, Slovenia, Sweden, Switzerland, Thailand, United Arab Emirates, United Kingdom
Bayer

Completed

Study to Compare the Effectiveness of Rivaroxaban (Xarelto) Versus Low-molecular-weight Heparin (LMWH) and Phenprocoumon for the Treatment and Secondary Prevention of Venous Thromboembolism in Routine Clinical Practice in Germany

Venous Thromboembolism

Germany
Bayer
External supplier: HEVA

Completed

A Study Related to the VOYAGER PAD Trial to Learn More About the Target Population for Xarelto in French Patients (PADELTO)

Peripheral Artery Disease

France
University of Edinburgh
NHS Lothian

Completed

Start or STop Anticoagulants Randomised Trial (SoSTART) (SoSTART)

Atrial Fibrillation | Intracranial Hemorrhages | Subarachnoid Hemorrhage | Intraventricular Hemorrhage | Atrial Flutter | Small Vessel Cerebrovascular Disease | Intracranial Hemorrhage, Hypertensive | Subdural Hematoma | Microhaemorrhage

United Kingdom
Cedars-Sinai Medical Center

Terminated

Alexa, What is Eliquis and Xarelto?

Patient Engagement | Patient Satisfaction

United States
Second Xiangya Hospital of Central South University

Completed

Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome (H-REPLACE)

Myocardial Infarction | Myocardial Ischemia | Acute Coronary Syndrome | Unstable Angina

China
Radboud University Medical Center

Completed

DUAL Pathway Inhibition to Improve Endothelial Function in Peripheral Artery Disease (DUAL-PAD)

Peripheral Artery Disease

Netherlands
Charite University, Berlin, Germany
Bayer; Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)

Terminated

Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19 (COVID-PREVENT)

COVID-19

Germany
Bayer
Janssen Research & Development, LLC

Completed

Study to Gather Information How Often Venous Thromboembolism Occurs in Prostate Cancer Patients in Sweden and How This Condition is Treated With Blood Thinners (PRACTISE)

Venous Thromboembolism (VTE)

Sweden
Bayer
Janssen, LP

Completed

Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical Practice (SiERRA UK)

Atrial Fibrillation

United Kingdom
Bayer
Janssen Research & Development, LLC

Completed

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)

Venous Thrombosis | Atrial Fibrillation | Acute Coronary Syndrome | Pulmonary Embolism

Germany
Bill & Melinda Gates Medical Research Institute

Terminated

A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)

COVID-19

United States, United Kingdom
Bayer
Janssen Scientific Affairs, LLC

Completed

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Venous Thrombosis | Atrial Fibrillation | Acute Coronary Syndrome | Pulmonary Embolism

Netherlands
Bayer
Janssen Scientific Affairs, LLC

Completed

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Venous Thrombosis | Atrial Fibrillation | Acute Coronary Syndrome | Pulmonary Embolism

Sweden
Bayer
Janssen Research & Development, LLC

Completed

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Venous Thrombosis | Atrial Fibrillation | Acute Coronary Syndrome | Pulmonary Embolism

United Kingdom
Chang Gung Memorial Hospital

Completed

Combined Topical Tranexamic Acid With Floseal® in Total Knee Arthroplasty

Osteoarthritis, Knee

Taiwan
University Hospital, Montpellier

Completed

Better Adherence With New Oral Anticoagulant in Atrial Fibrillation : Effectiveness of a Personalized Education Program (MONACO)

Non-valvular Atrial Fibrillation

France
University of Padova

Completed

Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee Arthroscopy (ERIKA)

Venous Thromboembolism | Haemorrhage

Italy
AIO-Studien-gGmbH
Bayer; Charite University, Berlin, Germany

Terminated

Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients

Cancer | Venous Thromboembolism

Germany
Bayer
Janssen Research & Development, LLC; RTI Health Solutions

Completed

Patient and Physician Knowledge of Key Safety Messages

Anticoagulation

Germany, United Kingdom, France, Spain
Bayer
Janssen Research & Development, LLC

Completed

Study to Gather Information on the Kidney Function of Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem) Treated With Rivaroxaban or Vitamin K Antagonists (ANTENNA)

Non-Valvular Atrial Fibrillation

United Kingdom
Pharmtechnology LLC
ClinPharmInvest, LLC

Unknown

Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 10 mg in Healthy Male Volunteers in Fasting Conditions

Bioequivalence

Russian Federation
Pirogov Russian National Research Medical University

Completed

Rivaroxaban With Diosmin in Long-term Treatment of Deep Vein Thrombosis (RIDILOTT-DVT)

Deep Vein Thrombosis | Postthrombotic Syndrome

Russian Federation
Bayer
Janssen Research & Development, LLC

Completed

A Trial to Learn How a New Liquid Form of Rivaroxaban Behaves and How Safe it is Compared to the Current Tablet Form of Rivaroxaban in Healthy Male Participants

Thromboembolic Disorders

Germany
Canadian Network for Observational Drug Effect...
Canadian Institutes of Health Research (CIHR); Drug Safety and Effectiveness...

Completed

Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs DOACs)

Myocardial Infarction | Ischemic Stroke | Atrial Fibrillation | All-cause Mortality | Systemic Embolization | Major Bleed

Canada
Canadian Network for Observational Drug Effect...
Canadian Institutes of Health Research (CIHR); Drug Safety and Effectiveness...

Completed

Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs Warfarin)

Myocardial Infarction | Ischemic Stroke | Atrial Fibrillation | All-cause Mortality | Systemic Embolization | Major Bleed

Canada
Bayer
Janssen Research & Development, LLC

Terminated

A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients. (PROTECT-AF)

Non-valvular Atrial Fibrillation

Norway
Bayer
Janssen Research & Development, LLC; Colorado Prevention Center

Completed

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities (VOYAGER PAD)

Peripheral Artery Disease

Poland, Belgium, France, Spain, China, Korea, Republic of, United States, Switzerland, Estonia, Portugal, Japan, Hungary, Canada, Netherlands, Finland, Austria, United Kingdom, Germany, Czechia, Thailand, Brazil, Denmark, Italy, Russian... and more
Bayer
Janssen Research & Development, LLC

Completed

Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon (ReLoaDeD)

Atrial Fibrillation

Germany
Bayer
Janssen Research & Development, LLC

Completed

Xarelto on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Treatment-naïve Asian Patients With Non-valvular Atrial Fibrillation (XaMINA)

Atrial Fibrillation

Korea, Republic of, Taiwan
RWTH Aachen University
Bayer

Completed

Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification

Atrial Fibrillation or Pulmonary Embolism | Need of Long Term Oral Anticoagulation Therapy (OAT) | Existent Coronary or Valvular Calcification, or Both and Agatston Score > 50 in at Least One Location

Germany
Bayer
Janssen Scientific Affairs, LLC

Completed

Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional Study (XASSURE)

Stroke

China
Bayer
Janssen Research & Development, LLC

Completed

Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients

Nonvalvular Atrial Fibrillation

United States
Bayer
Janssen Research & Development, LLC

Completed

Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on the Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 15 mg in Japanese Healthy Male Adult Subjects

Clinical Pharmacology

Japan
Bayer
Janssen Research & Development, LLC

Completed

Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 10 mg in Japanese Healthy Male Adult Subjects

Clinical Pharmacology

Japan
Mayo Clinic

Terminated

Vascular Boot Warming Program After Acute Deep Vein Thrombosis (DVT) ± Pulmonary Embolism (PE)

Acute DVT of Lower Extremity

United States
Ottawa Hospital Research Institute
University of Alberta; Hamilton Health Sciences Corporation; Queen Elizabeth...

Completed

Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines (TRIM-Line)

Cancer | Central Venous Catheter Thrombosis | Upper Extremity Deep Vein Thrombosis

Canada
The Young Investigator Group of Cardiovascular...

Completed

Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi (No-LVT)

Left Ventricular Thrombosis | Anticoagulants; Increased

Egypt
The Affiliated Hospital of Qingdao University

Completed

Pharmacokinetics and Bioequivalence of Rivaroxaban Tablet in Healthy Chinese Volunteers

Healthy Subjects

China
Hospital Geral Roberto Santos

Terminated

Rivaroxaban vs Warfarin in Patients With Metallic Prosthesis (RIWA)

Stroke | Valve Heart Disease | Anticoagulants and Bleeding Disorders | Prostheses and Implants

Brazil
Bayer
Janssen Scientific Affairs, LLC

Completed

Use of Direct Oral Anticoagulants in UK

Stroke

United Kingdom
University of North Carolina, Chapel Hill
National Heart, Lung, and Blood Institute (NHLBI)

Completed

The Effect of Rivaroxaban in Sickle Cell Disease

Sickle Cell Anemia | Sickle Cell-Beta0-Thalassemia

United States
Bayer
Janssen Research & Development, LLC

Completed

EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis (EINSTEIN Jr)

Venous Thromboembolism

Belgium, China, Hong Kong, United States, Switzerland, Spain, Russian Federation, Singapore, Canada, Germany, Netherlands, United Kingdom, Austria, Brazil, Israel, Italy, Mexico, Turkey, France, Australia, Finland, Hungary, Japan, Arg... and more
Florida Orthopaedic Institute
Orthopaedic Trauma Association

Unknown

Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs Rivaroxaban

Deep Vein Thrombosis | Venous Thromboembolism

United States
ECRI bv
Bayer; Rigshospitalet, Denmark; Cardialysis BV

Completed

Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT) (GALILEO-4D)

Cardiovascular Diseases | Thrombosis | Aortic Valve Stenosis | Heart Valve Diseases | Ventricular Outflow Obstruction

Germany, United States, Denmark, Switzerland, Netherlands, Sweden, Canada
Bayer
Janssen Research & Development, LLC

Terminated

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes (GALILEO)

Transcatheter Aortic Valve Replacement

Belgium, France, Germany, Spain, United States, Switzerland, Canada, Austria, United Kingdom, Korea, Republic of, Denmark, Italy, Netherlands, Poland, Czechia, Sweden, Norway
Asan Medical Center

Unknown

A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism (PRIORITY)

Stomach Cancer | Hepatocellular Carcinoma | Pancreatic Cancer | Esophageal Cancer | Duodenal Cancer | Esophagogastric Junction Cancer | Cancer-associated Thrombosis | Ampulla of Vater Cancer | Malignant Gastrointestinal Stromal Tumor | Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer)

Korea, Republic of
Bayer
Janssen Research & Development, LLC

Completed

Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction (CALLIPER)

Atrial Fibrillation

United States

Search clinical trials for: XARELTO

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations